Everything below concerns HPLC-MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
== Northern Hemisphere == In the Northern Hemisphere, there are two towns in Sakha, Russia that compete for the title of "Pole of Cold". These are Verkhoyansk (located at 67°33′N 133°23′E, altitude 127 metres (417 ft)) and Oymyakon (located at 63°15′N 143°9′E, altitude 745 metres (2,444 ft)). However, the World Meteorological Organization has recognized in 2020 a temperature of −69.6 °C (−93.3 °F), measured near the topographic summit of the Greenland Ice Sheet on 22 December 1991, as the lowest in the Northern Hemisphere. The record was measured at an automatic weather station and was uncovered after nearly 30 years. In December 1868 and then in February 1869 Ivan Khudyakov made the discovery of the Northern Pole of Cold by measuring a record temperature of −63.2 °C (−81.8 °F) in Verkhoyansk. Later, on January 15, 1885, a temperature of −67.8 °C (−90.0 °F) was registered there by Sergey Kovalik. This measurement was published in the Annals of the General Physical Observatory in 1892; by mistake it was written as −69.8 °C (−93.6 °F), which was later corrected. One can still find this incorrect value in some literature. The coldest reliably measured temperature in Verkhoyansk was −67.8 °C (−90.0 °F) on February 5 and 7 of 1892. On February 6, 1933, a temperature of −67.7 °C (−89.9 °F) was recorded at Oymyakon's weather station. At the time, this was the coldest reliably measured temperature for the Northern Hemisphere. The weather station is in a valley between Oymyakon and Tomtor.
== Proteins == The two main components of the soybean important in tofu making are the 11S component, containing glycinin, and the 7S subunit, containing hemagglutinins, lipoxygenases, b-amylase, and β-conglycinin. The major soy protein components, in the two fractions that make up 65–85% of the proteins in soybeans, include glycinin and β-conglycinin. The soybean protein consists of many different subunits, which are sensitive to heat, pH, and ionic strength and become unevenly distributed among soluble and particulate fractions due to hydrophilic and hydrophobic interaction because of the amino acid composition.
In 1957, the SAOCGA prohibited mixed-race competitions within its member bodies. In 1959, Dennis Brutus and others founded the South African Sports Association (SASA), which campaigned to allow non-white athletes to represent South Africa. The same year, IOC delegates questioned whether SAOCGA's operation violated the Olympic Charter's ban on discrimination. Reginald Honey, South Africa's IOC member, contended that nonwhite competitors had not been selected because none were of Olympic standard, and promised that any selected in future would be given passports. Brundage felt the discrimination rule only applied at the Olympics itself, not at domestic competition, and so South Africa was allowed to compete at the 1960 Olympics in Rome. The same year, it competed at the Winter Olympics for the first time. Its delegations were all white.
Sources: en.wikipedia.org
In late 2008, Valve released lifetime retail sales figures as part of a company profile in Game Informer magazine. The two main Half-Life games had sold 15.8 million units at retail (9.3 million for the first, 6.5 million for the second), while the Half-Life expansions had sold 1.9 million (Opposing Force: 1.1 million, Blue Shift: 800,000) and Half-Life 2 expansions 1.4 million units (all for Episode One) by the end of November 2008. Additionally, The Orange Box, which included Half-Life 2 and both of its episodic expansions, sold 3 million units at retail by November 2008. This put franchise sales at around 18.8 million full games (Half-Life: 9.3m, Half-Life 2: 6.5m) and approximately 6.3 million expansions (Opposing Force: 1.1m, Blue Shift: 0.8m, Episode One: 1.4m, Episode 2: 3.0m) at the same month. These figures did not account for digital sales. Half-Life: Counter-Strike sold 4.2 million units standalone by the same time, while its remake, Counter-Strike: Source was bundled with every sold retail copy of Half-Life 2. Forbes reported that, including digital sales, Half-Life 2 had sold over 12 million copies by February 2011.
Hydrogen isotope biogeochemistry (HIBGC) is the scientific study of biological, geological, and chemical processes in the environment using the distribution and relative abundance of hydrogen isotopes. Hydrogen has two stable isotopes, protium 1H and deuterium 2H, which vary in relative abundance on the order of hundreds of permil. The ratio between these two species can be called the hydrogen isotopic signature of a substance. Understanding isotopic fingerprints and the sources of fractionation that lead to variation between them can be applied to address a diverse array of questions ranging from ecology and hydrology to geochemistry and paleoclimate reconstructions. Since specialized techniques are required to measure natural hydrogen isotopic composition (HIC), HIBGC provides uniquely specialized tools to more traditional fields like ecology and geochemistry.
The following month an attempted coup d'état was staged by a sector of the army that sought to paralyze the democratic process and that only the decisive intervention of King Juan Carlos I managed to stop. After 23-F, the new UCD government presided by Leopoldo Calvo Sotelo managed to rule largely thanks to the support given by the PSOE and its leader Felipe González because the "self-destruction" of the UCD continued until October 1982, when new elections were held and were won overwhelmingly by the PSOE. Thus a party that had been one of the defeated parties in the civil war of 1936–1939 took power. After 1982, the democratic system was consolidated and Spain experienced a long period of political stability in which there was alternation in government between the left and the right in a peaceful manner following the dictates of the elections (the PSOE governed between 1982 and 1996 and between 2004 and 2011; the People's Party, which emerged from the "refounding" in 1989 of the Alianza Popular, between 1996 and 2004 and between 2011 and 2014). It was decisive for the achievement of political stability that the positions of the two major parties on the most important issues were not antagonistic and that there were no major "social fractures", the latter thanks to the development of the Welfare state and "social protection" policies. Also during those years, Spain actively participated in the transformation of the European Community, which it joined in 1986, in the European Union and in the establishment of the common currency, the euro.
Leukemia: diagnosis/recurrence, Biopsy;; Clinical Immunology Laboratory, Tissue lab "Aberrant cell population(phenotype); taxon;Biopsy(spec.)"; Clinical Immunology Laboratory, Tissue lab rearrangement of TCR/IgH- is. Biopsy;"Biopsy-(TCR+Igh- )-Immune rearrangement; clonality(0 1) = ?"; Clinical Immunology Laboratory, Tissue lab "Hem. Marker study, ADULTS over 16 years;Biopsy";Hem. Marker study, ADULTS over 16 years, Tissue biopsies;Hematology Marker Laboratory "Hem. Marker study, ADULTS over 16 years;Biopsy";Hem. Marker Examination, ADULTS over 16 years, Biopsy from Corpus Vitreum;Hematology Marker Laboratory Histologic examination of testis biopsy; Laboratory for Growth and Reproduction Miscellaneous analysis;DNA(spec.)-MLPA ocular melanoma; depends Miscellaneous analysis;FISH malignant melanoma choroidea; depends Helicobacter pylori (culture);Helicobacter pylori (culture); Clinical Microbiology Laboratory Tropheryma whipplei DNA/RNA;;Unknown Culture and resistance;Biopsy/tissue/bone tissue culture and resistance; Clinical Microbiology Laboratory
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.